These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 26254871)

  • 1. Transcriptional dysregulation in Huntington's disease: The role of histone deacetylases.
    Sharma S; Taliyan R
    Pharmacol Res; 2015 Oct; 100():157-69. PubMed ID: 26254871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Histone deacetylase inhibitors as therapeutic agents for polyglutamine disorders].
    Jiang H; Jia D; Tang B
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2010 Feb; 27(1):52-5. PubMed ID: 20140868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histone deacetylase inhibitors: a novel therapeutic approach to Huntington's disease (complex mechanism of neuronal death).
    Sadri-Vakili G; Cha JH
    Curr Alzheimer Res; 2006 Sep; 3(4):403-8. PubMed ID: 17017871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic Mechanisms Involved in Huntington's Disease Pathogenesis.
    Glajch KE; Sadri-Vakili G
    J Huntingtons Dis; 2015; 4(1):1-15. PubMed ID: 25813218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic knock-down of HDAC3 does not modify disease-related phenotypes in a mouse model of Huntington's disease.
    Moumné L; Campbell K; Howland D; Ouyang Y; Bates GP
    PLoS One; 2012; 7(2):e31080. PubMed ID: 22347433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic targeting of histone deacetylase: therapeutic potential in Parkinson's disease?
    Harrison IF; Dexter DT
    Pharmacol Ther; 2013 Oct; 140(1):34-52. PubMed ID: 23711791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetics of Huntington's Disease.
    Bassi S; Tripathi T; Monziani A; Di Leva F; Biagioli M
    Adv Exp Med Biol; 2017; 978():277-299. PubMed ID: 28523552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice.
    Thomas EA; Coppola G; Desplats PA; Tang B; Soragni E; Burnett R; Gao F; Fitzgerald KM; Borok JF; Herman D; Geschwind DH; Gottesfeld JM
    Proc Natl Acad Sci U S A; 2008 Oct; 105(40):15564-9. PubMed ID: 18829438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington's disease.
    Jia H; Pallos J; Jacques V; Lau A; Tang B; Cooper A; Syed A; Purcell J; Chen Y; Sharma S; Sangrey GR; Darnell SB; Plasterer H; Sadri-Vakili G; Gottesfeld JM; Thompson LM; Rusche JR; Marsh JL; Thomas EA
    Neurobiol Dis; 2012 May; 46(2):351-61. PubMed ID: 22590724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SAHA decreases HDAC 2 and 4 levels in vivo and improves molecular phenotypes in the R6/2 mouse model of Huntington's disease.
    Mielcarek M; Benn CL; Franklin SA; Smith DL; Woodman B; Marks PA; Bates GP
    PLoS One; 2011; 6(11):e27746. PubMed ID: 22140466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic modifications as novel therapeutic targets for Huntington's disease.
    Wang F; Fischhaber PL; Guo C; Tang TS
    Epigenomics; 2014 Jun; 6(3):287-97. PubMed ID: 25111483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of disease: Histone modifications in Huntington's disease.
    Sadri-Vakili G; Cha JH
    Nat Clin Pract Neurol; 2006 Jun; 2(6):330-8. PubMed ID: 16932577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic histone acetylation and deacetylation mechanisms in experimental models of neurodegenerative disorders.
    Konsoula Z; Barile FA
    J Pharmacol Toxicol Methods; 2012; 66(3):215-20. PubMed ID: 22902970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic knock-down of HDAC7 does not ameliorate disease pathogenesis in the R6/2 mouse model of Huntington's disease.
    Benn CL; Butler R; Mariner L; Nixon J; Moffitt H; Mielcarek M; Woodman B; Bates GP
    PLoS One; 2009 Jun; 4(6):e5747. PubMed ID: 19484127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington's disease.
    Pallos J; Bodai L; Lukacsovich T; Purcell JM; Steffan JS; Thompson LM; Marsh JL
    Hum Mol Genet; 2008 Dec; 17(23):3767-75. PubMed ID: 18762557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulating epigenetic HAT activity for reinstating acetylation homeostasis: A promising therapeutic strategy for neurological disorders.
    Ganai SA; Banday S; Farooq Z; Altaf M
    Pharmacol Ther; 2016 Oct; 166():106-22. PubMed ID: 27411674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetics in Neurodegenerative Diseases: The Role of Histone Deacetylases.
    Sharma S; Sarathlal KC; Taliyan R
    CNS Neurol Disord Drug Targets; 2019; 18(1):11-18. PubMed ID: 30289079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histone deacetylases in cardiac fibrosis: current perspectives for therapy.
    Tao H; Shi KH; Yang JJ; Huang C; Zhan HY; Li J
    Cell Signal; 2014 Mar; 26(3):521-7. PubMed ID: 24321371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitors of HDACs--effective drugs against cancer?
    Müller S; Krämer OH
    Curr Cancer Drug Targets; 2010 Mar; 10(2):210-28. PubMed ID: 20201785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of histone deacetylase inhibitors as therapeutics for neurodegenerative diseases.
    Soragni E; Xu C; Cooper A; Plasterer HL; Rusche JR; Gottesfeld JM
    Methods Mol Biol; 2011; 793():495-508. PubMed ID: 21913121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.